| Q48367339 | A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels |
| Q36662001 | A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma |
| Q34278435 | A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice |
| Q28263206 | Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells |
| Q51428846 | Asbestos and the lung in the 21st century: an update. |
| Q33623718 | Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum |
| Q34056345 | Auto-antibodies to β-F1-ATPase and vimentin in malignant mesothelioma |
| Q28082088 | Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure |
| Q28387194 | Biomarkers and prognostic factors for mesothelioma |
| Q55459882 | Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on. |
| Q37328307 | Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. |
| Q41593380 | Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot? |
| Q37335377 | Biomarkers for malignant pleural mesothelioma: current status |
| Q55006991 | Biomarkers in malignant pleural mesothelioma: current status and future directions. |
| Q35997395 | Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know |
| Q33556551 | CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives |
| Q38118298 | Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers |
| Q51206145 | Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers. |
| Q64235291 | Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP) |
| Q35904195 | Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study. |
| Q36723787 | Clinical significance of serum CA125 in diffuse malignant mesothelioma |
| Q39798008 | Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer |
| Q41920935 | Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma |
| Q85107220 | Comparison between Plasma and Serum Osteopontin Levels: Usefulness in Diagnosis of Epithelial Malignant Pleural Mesothelioma |
| Q40189722 | Comparison of statistical methods for detection of serum lipid biomarkers for mesothelioma and asbestos exposure |
| Q37176647 | Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum |
| Q37086026 | Current concepts in malignant pleural mesothelioma. |
| Q34788477 | Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid |
| Q35208928 | Delta neutrophil index as a promising prognostic marker in out of hospital cardiac arrest |
| Q39434249 | Diagnosis and prognosis-review of biomarkers for mesothelioma. |
| Q33890558 | Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. |
| Q26849620 | Discovery of new biomarkers for malignant mesothelioma |
| Q42863986 | Effectiveness of serum megakaryocyte potentiating factor in evaluating the effects of chrysotile and its heated products on respiratory organs |
| Q35092711 | Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma |
| Q43117575 | Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population |
| Q35678085 | Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q28394028 | Guidelines for the diagnosis and treatment of malignant pleural mesothelioma |
| Q28535472 | Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma |
| Q34760760 | Identification of novel markers for the diagnosis of malignant pleural mesothelioma |
| Q53248796 | Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report. |
| Q85818463 | Individual predictors of increased serum mesothelin in asbestos-exposed workers |
| Q44173242 | Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. |
| Q93048382 | Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives |
| Q37499806 | MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. |
| Q21202901 | Malignant mesothelioma |
| Q47098675 | Malignant mesothelioma: Canadian perspective and research directions |
| Q34513958 | Malignant pleural mesothelioma: an update on diagnosis and treatment options |
| Q37217764 | Malignant pleural mesothelioma: current and future perspectives |
| Q37277451 | Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG). |
| Q43179891 | Management of pleural disease |
| Q37139387 | Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. |
| Q28392693 | Mesothelioma - Update on Diagnostic Strategies |
| Q93088436 | MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions |
| Q36320997 | Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin |
| Q52581757 | New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma. |
| Q34998586 | Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma |
| Q92957225 | Novel single-chain variant of antibody against mesothelin established by phage library |
| Q34839346 | Osteopontin modulates inflammation, mucin production, and gene expression signatures after inhalation of asbestos in a murine model of fibrosis |
| Q33866338 | Osteopontin, asbestos exposure and pleural plaques: a cross-sectional study |
| Q39747942 | Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. |
| Q37703338 | Osteopontin: an effector and an effect of tumor metastasis. |
| Q52672878 | Overexpressed genes in malignant pleural mesothelioma: implications in clinical management. |
| Q33815929 | Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis |
| Q39977787 | Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma |
| Q42956963 | Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease |
| Q41234207 | Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis |
| Q38585167 | Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma |
| Q39124644 | Prognostication and monitoring of mesothelioma using biomarkers: a systematic review |
| Q37623620 | Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma |
| Q54678404 | Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. |
| Q26860736 | Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis |
| Q54957187 | Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma. |
| Q37862752 | Soluble markers for diagnosis of malignant pleural mesothelioma |
| Q53407433 | Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. |
| Q35558563 | The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma |
| Q37806309 | Translational advances in pleural malignancies |
| Q48273744 | Usefulness of mean platelet volume as a marker for clinical outcomes after out-of-hospital cardiac arrest: a retrospective cohort study. |
| Q33781142 | What's the place of immunotherapy in malignant mesothelioma treatments? |
| Q82061962 | [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma] |
| Q81193481 | [Occupational respiratory cancers] |